Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Biotechnology
  • GSK pens $1.3B Hutchmed deal for early-stage KRAS-EGFR cancer asset

GSK pens $1.3B Hutchmed deal for early-stage KRAS-EGFR cancer asset

September 3, 2026Posted inBiotechnology

GSK is handing over $110 million upfront to Hutchmed in a deal worth up to $1.295 billion to get its hands on a first-in-class oncology candidate.

Post navigation

Previous Post
Ultragenyx fails phase 3 Angelman test, plots ‘significant expense reductions’
Next Post
AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trial

Recent Posts

  • Italian Citizens Favor Farm Artificial Intelligence While Expressing Notable Response Uncertainty
  • Static Lift Corrections Extend Linear Theory for Fixed-Angle Airfoils in Gusts
  • Cross-Environment 3D Documentation Workflow Links Cultural Heritage Mapping to Natural Hazard Simulations
  • Sustainable Liquid Chromatography Technique Simultaneously Quantifies Avibactam and Aztreonam
  • Engineers Transform Insulating Kaolin Ceramics into Conductive Monoliths for Fuel Oxidation

Archives

  • November 2026
  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • September 2024
  • August 2024
  • March 2024
  • September 2023

Privacy Policy    Terms

Scroll to Top